Credit Suisse Group Lowers AstraZeneca plc (LON:AZN) Price Target to GBX 4,700
AstraZeneca plc (LON:AZN) had its price objective trimmed by Credit Suisse Group from GBX 5,000 ($65.95) to GBX 4,700 ($62.00) in a research report report published on Friday, Marketbeat.com reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
AZN has been the topic of several other reports. Morgan Stanley restated an overweight rating and issued a GBX 5,600 ($73.87) price target on shares of AstraZeneca plc in a research report on Friday, June 23rd. Deutsche Bank AG restated a buy rating on shares of AstraZeneca plc in a research report on Monday, May 22nd. Shore Capital restated a sell rating on shares of AstraZeneca plc in a research report on Thursday, May 4th. Beaufort Securities restated a hold rating on shares of AstraZeneca plc in a research report on Monday, April 3rd. Finally, Barclays PLC restated an overweight rating and issued a GBX 6,000 ($79.15) price target on shares of AstraZeneca plc in a research report on Monday, June 5th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the stock. AstraZeneca plc currently has a consensus rating of Hold and an average price target of GBX 5,046.95 ($66.57).
Shares of AstraZeneca plc (LON AZN) opened at 4571.00 on Friday. The stock’s market capitalization is GBX 57.87 billion. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The stock’s 50 day moving average price is GBX 5,140.37 and its 200 day moving average price is GBX 4,864.62.
The business also recently announced a dividend, which will be paid on Monday, September 11th. Investors of record on Thursday, August 10th will be given a GBX 68.90 ($0.91) dividend. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, August 10th.
In related news, insider Nazneen Rahman bought 39 shares of the stock in a transaction that occurred on Thursday, July 27th. The shares were acquired at an average price of GBX 4,370 ($57.64) per share, with a total value of £1,704.30 ($2,248.12).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.